Association of calcium channel blocker use with clinical outcome of COVID-19: A meta-analysis

• Main Authors: Mochamad Yusuf Alsagaff, -, Eka Prasetya Budi Mulia, -, Irma Maghfirah, -, Kevin Luke, -, David Nugraha, -, Dita Aulia Rachmi, -, Imanita Septianda, -, Maya Qurota A'yun, -
• Format: Article PeerReviewed
• Language: English; English; English; English
• Published: Elsevier 2021
• Subjects: R5-920 Medicine (General)
• Online Access: https://repository.unair.ac.id/126040/1/9.%20Association%20of%20Calcium%20Channel%20Blocker%20Use%20on%20Clinical%20Outcome%20of%20Covid%2019%20A%20Meta-analysis_DMS%20CRR%202021.pdf; https://repository.unair.ac.id/126040/2/9.%20Korespondensi.pdf; https://repository.unair.ac.id/126040/3/karil%209.pdf; https://repository.unair.ac.id/126040/4/9.%20Turnitin.pdf; https://repository.unair.ac.id/126040/; https://www.sciencedirect.com/science/article/pii/S1871402121002307?via%3Dihub; https://doi.org/10.1016/j.dsx.2021.102210
• Institution: Universitas Airlangga

Aims This meta-analysis aims to analyze the association of calcium channel blocker (CCB) use with COVID-19 clinical outcomes. Methods PubMed, ProQuest, Science Direct, Scopus, and medRxiv databases were searched systematically in a limited period. The primary outcome was mortality. Results A total of 119,298 patients from 31 eligible studies were included. Pooled analysis of the random-effect model revealed CCB was not associated with reduced mortality (OR = 1.21 [95%CI: 0.98–1.49], p = 0.08). Interestingly, subgroup analysis in hypertensive patients revealed significantly reduced mortality (OR = 0.69 [95%CI: 0.52–0.91], p = 0.009). Conclusion CCB usage was not associated with the outcome of COVID-19. However, CCB was associated with a decreased mortality rate in hypertensive COVID-19 patients.